Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review
Diagnostics · 27.03.2023 · 13 (7) · 1257
DOI: 10.3390/diagnostics13071257 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 27.03.2023. Verfasst von Marvin J Fritzler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anti-nuclear (ANA) are present in approximately 90% of systemic sclerosis (SSc) patients and are key biomarkers in supporting the diagnosis and determining the prognosis of this disease. In addition to the classification criteria autoantibodies for SSc [i.e., anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA polymerase III], other autoantibodies have been associated with important SSc phenotypes. Among them, anti-U11/U12 ribonucleoprotein (RNP) antibodies, also known as anti-RNPC-3, were first reported in a patient with SSc, but very little is known about their association and clinical utility. The U11/U12 RNP macromolecular complex consists of several proteins involved in alternative mRNA splicing. More recent studies demonstrated associations of anti-anti-U11/U12 antibodies with SSc and severe pulmonary fibrosis as well as with moderate to severe gastrointestinal dysmotility. Lastly, anti-U11/U12 autoantibodies have been strongly associated with malignancy in SSc patients. Here, we aimed to summarize the knowledge of anti-U11/U12/RNPC-3 antibodies in SSc, including their seroclinical associations in a narrative literature review.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
- Research and Development, Werfen, Autoimmunity Headquarters and Technology Center, San Diego, CA 92131-1638, USA.
- Scleroderma Unit and (Referral) Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milan, 20122 Milano, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, 50121 Firenze, Italy.
- Department of Immunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
- Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
ORCID-Profile: Lorenzo Beretta, Boaz Palterer, Maria Teresa Sanz-Martínez, Alfredo Guillen-Del-Castillo, Ana Marín, Carmen Pilar Simeón-Aznar
Zitieren
APA
Fritzler, M. J., Bentow, C., Beretta, L., Palterer, B., Perurena-Prieto, J., Sanz-Martínez, M. T., Guillen-Del-Castillo, A., Marín, A., Fonollosa-Pla, V., Callejas-Moraga, E., Simeón-Aznar, C. P., & Mahler, M. (2023). Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review. Diagnostics, 13(7), 1257. https://doi.org/10.3390/diagnostics13071257
Vancouver
Fritzler MJ, Bentow C, Beretta L, Palterer B, Perurena-Prieto J, Sanz-Martínez MT, et al. Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review. Diagnostics. 2023;13(7):1257. doi:10.3390/diagnostics13071257
BibTeX
@article{Fritzler2023,
author = {Fritzler, Marvin J and Bentow, Chelsea and Beretta, Lorenzo and Palterer, Boaz and Perurena-Prieto, Janire and Sanz-Martínez, Maria Teresa and Guillen-Del-Castillo, Alfredo and Marín, Ana and Fonollosa-Pla, Vicent and Callejas-Moraga, Eduardo and Simeón-Aznar, Carmen Pilar and Mahler, Michael},
title = {Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {7},
pages = {1257},
doi = {10.3390/diagnostics13071257}
}
EUVIMED